Eli Lilly's rheumatoid arthritis drug helps recovery in Covid-19 patients

Coronavirus chronicle

Reuters
14 September, 2020, 05:00 pm
Last modified: 14 September, 2020, 05:08 pm
The US drugmaker said the drug, in combination with Gilead Sciences Inc's remdesivir, met the main goal of shortening recovery when compared to remdesivir alone
The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. Picture taken February 1, 2018. REUTERS/Vincent Kessler

Eli Lilly and Co said on Monday its rheumatoid arthritis drug baricitinib shortened the time taken to recover from Covid-19 in hospitalized patients when taken in combination with Gilead Sciences Inc's antiviral remdesivir.

Lilly said the drug, which is branded as Olumiant, in combination remdesivir showed a roughly one-day reduction in median recovery time versus patients treated with remdesivir alone.

Based on the results from the trial, which tested more than 1,000 patients, Lilly said it plans to discuss the potential for an emergency use authorization (EUA) with the US Food and Drug Administration.

Remdesivir is at the forefront of the fight against Covid-19 after the drug was granted an EUA in May after trial data showed the antiviral drug helped shorten hospital recovery time.

The drug, which has been licensed by Lilly from Incyte Corp , could potentially help suppress a potentially lethal immune response to Covid-19 called "cytokine storm".

Related Topics

Top News

Eli Lilly / COVID-19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.